In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Elevance Health Inc (NYSE: ELV) closed at $422.26 down -1.98% from its previous closing price of $430.77. In other words, the price has decreased by -$1.98 from its previous closing price. On the day, 2.21 million shares were traded. ELV stock price reached its highest trading level at $435.61 during the session, while it also had its lowest trading level at $420.76.
Ratios:
For a deeper understanding of Elevance Health Inc’s stock, let’s take a closer look at its various ratios. In the meantime, Its Debt-to-Equity ratio is 0.62 whereas as Long-Term Debt/Eq ratio is at 0.56.
On July 18, 2024, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $646 to $530.
On June 24, 2024, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $643.Morgan Stanley initiated its Overweight rating on June 24, 2024, with a $643 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 18 ’24 when Kendrick Charles Morgan JR sold 7,417 shares for $432.14 per share. The transaction valued at 3,205,182 led to the insider holds 8,423 shares of the business.
Kendrick Charles Morgan JR bought 7,417 shares of ELV for $3,206,221 on Oct 18 ’24. On Aug 05 ’24, another insider, PERU RAMIRO G, who serves as the Director of the company, sold 753 shares for $531.52 each. As a result, the insider received 400,235 and left with 8,744 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELV now has a Market Capitalization of 97931812864 and an Enterprise Value of 89224388608. As of this moment, Elevance’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.39, and their Forward P/E ratio for the next fiscal year is 11.24. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.71. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.56 while its Price-to-Book (P/B) ratio in mrq is 2.24. Its current Enterprise Value per Revenue stands at 0.513 whereas that against EBITDA is 7.863.
Stock Price History:
Over the past 52 weeks, ELV has reached a high of $567.26, while it has fallen to a 52-week low of $397.98. The 50-Day Moving Average of the stock is -19.42%, while the 200-Day Moving Average is calculated to be -18.52%.
Shares Statistics:
For the past three months, ELV has traded an average of 1.12M shares per day and 2281270 over the past ten days. A total of 233.07M shares are outstanding, with a floating share count of 230.96M. Insiders hold about 0.41% of the company’s shares, while institutions hold 91.54% stake in the company. Shares short for ELV as of 1727654400 were 2416411 with a Short Ratio of 2.17, compared to 1724976000 on 1776654. Therefore, it implies a Short% of Shares Outstanding of 2416411 and a Short% of Float of 1.04.
Dividends & Splits
According to the company, the forward annual dividend rate for ELV is 6.37, from 6.37 in the trailing year. Against a Trailing Annual Dividend Yield of 0.014787474The stock’s 5-year Average Dividend Yield is 1.14.
Earnings Estimates
The stock of Elevance Health Inc (ELV) is currently being evaluated by 19.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $10.91, with high estimates of $12.41 and low estimates of $8.34.
Analysts are recommending an EPS of between $37.31 and $32.98 for the fiscal current year, implying an average EPS of $35.32. EPS for the following year is $38.64, with 23.0 analysts recommending between $42.01 and $34.63.
Revenue Estimates
A total of 14 analysts believe the company’s revenue will be $44.26B this quarter.It ranges from a high estimate of $45.98B to a low estimate of $41.33B. As of the current estimate, Elevance Health Inc’s year-ago sales were $42.45BFor the next quarter, 14 analysts are estimating revenue of $45.19B. There is a high estimate of $47.06B for the next quarter, whereas the lowest estimate is $43.05B.
A total of 16 analysts have provided revenue estimates for ELV’s current fiscal year. The highest revenue estimate was $176.84B, while the lowest revenue estimate was $167.97B, resulting in an average revenue estimate of $173.67B. In the same quarter a year ago, actual revenue was $170.21BBased on 17 analysts’ estimates, the company’s revenue will be $186.03B in the next fiscal year. The high estimate is $191.39B and the low estimate is $178.28B.
